Intas Pharmaceuticals Limited on FDA Import Alert List
Harrow Launches Next-Generation Compounded Atropine Formulations
Enforcement Report - Week of January 18, 2023
Enforcement Report - Week Of June 01, 2022
Enforcement Report - Week of November 17, 2021
BRIDGEWATER, N.J. and CLERMONT-FERRAND, France, Jan. 28, 2021 (GLOBE NEWSWIRE) -- Nevakar Inc. (“Nevakar”), a biopharmaceutical company developing multiple assets in the ophthalmic and injectable areas, and Laboratoires Théa (“Théa”) announced today that they recently entered into an exclusive licensing agreement for the commercialization of NVK-002 in Europe. NVK-002 is a proprietary, investigational, preservative-free eye drop administered nightly and intended for slowing the progression of myopia in children ages three to 17. It is currently under clinical evaluation in the CHAMP (Childhood Atropine for Myopia Progression) study, a Phase III clinical trial being carried out in the U.S. and Europe.
Enforcement Report - Week of April 24, 2019
Enforcement Report - Week of November 7, 2018
Enforcement Report - Week of August 22, 2018
Treatments for peripheral neuropathy, the numbness and pain most commonly felt in the fingers, arms and legs due to nerve damage, tend to focus on managing pain. But an international team may have found an alternative approach that could potentially reverse symptoms with a class of drugs already in use for other conditions.